Finance

Lists
Q3 2026 earnings • in 1 day
See details
BCRX:NASDAQ
BioCryst Pharmaceuticals Inc
$8.24
-2.66%
(-0.23) 1D
$8.14
-1.27% (-0.10)
After hours
Closed: Nov 2, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BCRX...
Open
$8.49
High
$8.52
Low
$8.22
Mkt. cap
2.11B
Avg. vol.
5.12M
Volume
0.00
52-wk high
$11.22
52-wk low
$6.23
EPS
-$1.50
Beta
0.55
Shares outstanding
255.54M
No. of employees
435
Open
$8.49
High
$8.52
Low
$8.22
Mkt. cap
2.11B
Avg. vol.
5.12M
Volume
0.00
52-wk high
$11.22
52-wk low
$6.23
EPS
-$1.50
Beta
0.55
Shares outstanding
255.54M
No. of employees
435
News stories
From web sources and news partners
Profile
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases. BioCryst's antiviral drug peramivir was approved by the FDA in December 2014 and berotralstat was approved in December 2020. Wikipedia
About BioCryst Pharmaceuticals Inc
CEOJon P. Stonehouse
Employees435
Founded1986
HeadquartersDurham, North Carolina, United States
SectorBiotechnology
Websitebiocryst.com
Analyst ratings
Based on 8 analysts giving stock ratings to BCRX in the past 3 months
Strong buy
Buy
6
Hold
2
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for BCRX in the last 3 months.
Highest
Current $8.24
$32.00 (+288.11%)
Average
$19.25 (+133.47%)
Lowest
$11.00 (+33.41%)
Analyst
Recommendation
Action
Price target
Projected
Date
Stacy Ku
TD Cowen
Buy
Maintained
$30.00
+263.9%
10/21/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$15.00
+81.9%
10/09/2026
Brian Abrahams
RBC Capital
Hold
Maintained
$11.00
+33.4%
10/08/2026
Jessica Fye
J.P. Morgan
Hold
Reiterated
$13.00
+57.7%
09/30/2026
Serge Belanger
Needham
Buy
Maintained
$16.00
+94.1%
09/08/2026
Unknown Analyst
Evercore ISI
Buy
Maintained
$17.00
+106.2%
08/10/2026
Andrew Fein
H.C. Wainwright
Buy
Maintained
$32.00
+288.1%
08/06/2026
Laura Chico
Wedbush
Buy
Maintained
$20.00
+142.6%
08/06/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
$29.00
+251.7%
06/30/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$28.00
+239.6%
05/07/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Initiated
$17.00
+106.2%
02/18/2026
Next call in 30:47:31
Wed, Nov 4, 8:30 AM
Fiscal period
Q3 2026
- / $0.12
Revenue / Est. (USD)
- / 165.68M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
159.40M
406.56M
156.41M
218.25M
Cost of goods sold
46.79M
48.35M
65.70M
55.81M
Cost of revenue
46.79M
48.35M
65.70M
55.81M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
83.01M
91.51M
94.55M
63.98M
Operating expense
83.01M
91.51M
94.55M
63.98M
Total operating expenses
129.80M
139.86M
160.25M
119.78M
Operating income
29.59M
266.70M
-3.84M
98.46M
Other non operating income
2.67M
5.86M
-1.46M
260.00K
EBT including unusual items
12.13M
248.02M
-720.81M
79.47M
EBT excluding unusual items
14.87M
261.19M
-23.05M
79.47M
Income tax expense
-769.00K
2.17M
1.00M
1.08M
Effective tax rate
-6.34%
0.88%
-0.14%
1.36%
Other operating expenses
-
-
-
-
Net income
12.90M
245.84M
-721.81M
78.40M
Net profit margin
8.09%
60.47%
-461.48%
35.92%
Earnings per share
0.16
0.21
0.14
0.35
Interest and investment income
2.24M
2.89M
2.26M
2.43M
Interest expense
-19.66M
-14.14M
-19.78M
-21.71M
Net interest expenses
-17.42M
-11.24M
-17.52M
-19.28M
Depreciation and amortization charges
-
-
-
-
EBITDA
31.56M
267.55M
-2.78M
98.95M
Gain or loss from assets sale
-550.00K
-3.57M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps